Dive Brief:Vaccine sales for French pharmaceutical company Sanofi dipped in the fourth quarter amid shifting U.S. policy and rhetoric that’s leading to declining immunization rates. In disclosing annual earnings Thursday, Sanofi revealed that its fourth-quarter vaccine sales declined 2.5% and that it anticipates “slightly negative growth” for its shots in 2026. Flu vaccine performance, though, was offset by falling numbers for other immunizations, including a shot for meningitis and its preventive RSV antibody Beyfortus. Sanofi still maintains its “leadership in influenza and RSV despite a challenging environment,” CEO Paul Hudson told analysts. Repeated false claims about the risks of vaccination, combined with an overhaul of the key panel guiding U.S. vaccine recommendations, have increased already growing hesitancy and spurred disease outbreaks.